Mountain View, California, February 2, 2005 – Ingenuity announced today that Wyeth Pharmaceuticals, Inc. (NYSE: WYE) has expanded its licensing of the IPA software, and extended its use into new areas of therapeutic research. The latest release of the IPA application provides a novel approach for scientists to compare and understand biological states, a critical capability for decreasing attrition and speeding time to market in pharmaceutical research and development.
“Wyeth has embraced pathways analysis software as an increasingly important element to successful therapeutic research and development,” stated Jake Leschly, President and CEO of Ingenuity. “Ingenuity is pleased to be providing expanded access to IPA to more Wyeth researchers, particularly downstream in the pharmaceutical value chain.”
About Ingenuity Systems
Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View, California.www.ingenuity.com.